BioSight

BioSight is a privately-held pharmaceutical development company established in 2000. The company focuses on developing novel anti-cancer drugs and innovative chemotherapy prodrugs to address unmet clinical needs. Its targeted chemotherapy portfolio includes novel molecules and new chemotherapy prodrugs that target and kill cancer cells while significantly reducing systemic toxicity associated with conventional chemotherapy. Thus, the company’s development strategy aims to revolutionize cancer treatment and provide safe and effective therapies for cancer patients worldwide. The company's lead proprietary product, BST-236, is in Phase 2b for frontline treatment of acute myeloid leukemia (AML). Other clinical studies for leukemia and myelodysplastic syndromes (MDS), as a single agent and in combination with other drugs, are being prepared.